Current Treatment Practices for Children and Adults With Trichotillomania: Consensus Among Experts

Very little is known regarding the efficacy of pharmacological and psychosocial treatments for children and adults with trichotillomania (TTM). Given this dearth of information, the present investigation sought to examine the treatment practices of members of the nationally recognized Trichotillomania Learning Center–Scientific Advisory Board (TLC-SAB) and practitioners known by members of the TLC-SAB to possess extensive experience working with this population. The responses of 67 practitioners to an Internet-based survey were examined. Our results clearly indicate that cognitive-behavioral treatment (CBT) is the treatment of choice for both children and adults with TTM. In particular, several components of CBT (i.e., awareness training, self-monitoring, competing response training, habit reversal training, and stimulus control) are implemented most often. Selective serotonin reuptake inhibitors (SSRIs, e.g., citalopram, fluoxetine) and serotonin-norepinepherine reuptake inhibitors (SNRIs, e.g., venlafaxine, duloxetine) were prescribed most frequently; however, these results are preliminary given our small sample of prescribing practitioners (n = 11). Taken together, these findings are a critical starting point to advancing the understanding of efficacious interventions for the treatment of individuals with TTM. Clinical and research implications, future areas of research, and study limitations are discussed.